Abstract
The dopaminergic system plays a major role in neurological and psychiatric disorders such as Parkinsons disease, Huntingtons disease, tardive dyskinea and schizophrenia. Knowledge on altered dopamine synthesis, receptor densities and status are important for understanding the mechanisms underlying the pathogenesis and therapy of diseases. PET provides a non-invasive tool to investigate these features in vivo, provided the availability of suitable radiopharmaceuticals. To investigate presynaptic function, PET-tracers have been developed to measure dopamine synthesis and transport. For the former the most commonly used tracers are 6-[18F]FDOPA and 6-[18F]FMT, whereas for the latter several 11C/18F-labeled tropane analogues are being clinically used. Postsynaptically, dopamine exerts actions through several subtypes of the dopamine receptor. The dopamine receptor family consists of 5 subtypes D1-D5. In order to investigate the role of each receptor subtype, selective and high-affinity PETradioligands are required. For the dopamine D1-subtype the most commonly used ligand is [11C]SCH 23390 or [11C]NNC 112, whereas for the D2/D3-subtype [11C]raclopride is a common tracer. [18 F]Fallypride is a suitable PET-tracer for the investigation of extrapyramidal D2-receptors. For the other subtypes no suitable radioligands have been developed yet. This paper gives an overview of the current status on dopamine PET-tracers and the development of new lead compounds as potential PET-tracers by medicinal chemistry.
Keywords: positron emission tomography, dopamine receptor, dopamine transporter, Dopamine synthesis
Current Medicinal Chemistry
Title: PET Tracers for Imaging of the Dopaminergic System
Volume: 13 Issue: 18
Author(s): Kentaro Hatano, Kiichi Ishiwata and Philip H. Elsinga
Affiliation:
Keywords: positron emission tomography, dopamine receptor, dopamine transporter, Dopamine synthesis
Abstract: The dopaminergic system plays a major role in neurological and psychiatric disorders such as Parkinsons disease, Huntingtons disease, tardive dyskinea and schizophrenia. Knowledge on altered dopamine synthesis, receptor densities and status are important for understanding the mechanisms underlying the pathogenesis and therapy of diseases. PET provides a non-invasive tool to investigate these features in vivo, provided the availability of suitable radiopharmaceuticals. To investigate presynaptic function, PET-tracers have been developed to measure dopamine synthesis and transport. For the former the most commonly used tracers are 6-[18F]FDOPA and 6-[18F]FMT, whereas for the latter several 11C/18F-labeled tropane analogues are being clinically used. Postsynaptically, dopamine exerts actions through several subtypes of the dopamine receptor. The dopamine receptor family consists of 5 subtypes D1-D5. In order to investigate the role of each receptor subtype, selective and high-affinity PETradioligands are required. For the dopamine D1-subtype the most commonly used ligand is [11C]SCH 23390 or [11C]NNC 112, whereas for the D2/D3-subtype [11C]raclopride is a common tracer. [18 F]Fallypride is a suitable PET-tracer for the investigation of extrapyramidal D2-receptors. For the other subtypes no suitable radioligands have been developed yet. This paper gives an overview of the current status on dopamine PET-tracers and the development of new lead compounds as potential PET-tracers by medicinal chemistry.
Export Options
About this article
Cite this article as:
Hatano Kentaro, Ishiwata Kiichi and Elsinga H. Philip, PET Tracers for Imaging of the Dopaminergic System, Current Medicinal Chemistry 2006; 13 (18) . https://dx.doi.org/10.2174/092986706777935258
DOI https://dx.doi.org/10.2174/092986706777935258 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNA-451 Aggravates Kainic Acid-induced Seizure and Neuronal Apoptosis by Targeting GDNF
Current Neurovascular Research Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research Predictability of Sustained Virological Response to Pegylated Interferon Alpha-2b Plus Ribavirin Therapy by Week-8 Viral Response in HIVPositive Patients with Chronic Hepatitis C Virus Infection
Current HIV Research Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Synthesis of N1- and N8-(γ -L-Glutamyl)spermidines and (γ -L-Glutamyl) putrescine
Letters in Organic Chemistry N-Valproyl-L-Phenylalanine as New Potential Antiepileptic Drug: Synthesis, Characterization and In Vitro Studies on Stability, Toxicity and Anticonvulsant Efficacy
Medicinal Chemistry Allergy and Inflammation: An Immunological and Therapeutic Approach
Recent Patents on Inflammation & Allergy Drug Discovery The Emerging Role of TRP Channels in Mechanisms of Temperature and Pain Sensation
Current Neuropharmacology Peripheral Immune Signatures in Alzheimer Disease
Current Alzheimer Research Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo
Current Pharmaceutical Design Bioinformatic Application in Proteomic Research on Biomarker Discovery and Drug Target Validation
Current Bioinformatics Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science The Effect of Casein Kinase 2 Inhibition on three Leukemic Cell Lines
Current Drug Therapy Focused Microarray Analysis: Characterization of Phenomes by Gene Expression Profiling
Current Pharmacogenomics Organotypic Cultures as Tool to Test Long-Term Effects of Chemicals on the Nervous System
Current Medicinal Chemistry Pharmacology, Systematic Review and Recent Clinical Trials of Metadoxine
Reviews on Recent Clinical Trials Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Cerebral Small Vessel Disease is Associated with Genetic Variations in CYP2J
Current Neurovascular Research Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design